AP4B1

Across TCGA pan-cancer cohorts, AP4B1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated AP4B1 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher AP4B1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AP4B1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

OV, HNSC, and UCEC are the cancer types where AP4B1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.190	0.542	.018	18	view →
HNSC	OS	Median	II,III,IV	0.198	0.716	.001	15	view →
UCEC	DFS	Median	All	0.976	0.826	.008	10	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
PAAD	OS	Median	All	0.131	0.640	.012	6	view →
STAD	DFS	Median	All	1.000	0.387	.033	6	view →
SKCM	OS	Median	III,IV	0.253	0.729	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

AP4B1–OV (DFS)

Open the OV breakdown →